Cultural and Religious Awareness for Online Ministries

This purpose of this project was to address the cultural and religious barriers when answering various questions concerning the Bible and daily living for online ministries. In order to be able to effectively convey the gospel message, any online ministry and its staff members need a good understanding of varying and different cultures or religions via online resources of those different religions and cultures. These resources aid in the efficiency and effectiveness of the online ministry staff by enhancing cultural and religious awareness. These resources decrease follow-up questions for further clarification of original questions as well as decrease the reassignment of questions. These resources are used in training and evaluating ministerial staff in their understanding and effectiveness. These resources increase the positive outcome to a better understanding of the salvific message that increase of professions of faith globally. An explanatory sequential design has been used as a mixed methodology. A Likert survey and multiple open ended questions were conducted with the eight (8) editors of GQM, all of whom gave their perception of what kind of resources would be available and how it can be accessed. The literature review was enlightening particularly the Peace Child demonstrating the need for understanding other cultures and religions to convey the salvific message. The findings are that any online ministry preparing to evangelize through technology, is in need of such resources, tools, and training. For online ministries, the mission field is a global stage and there are various cultures, religions, and Christian denominations worldwide

DINOSAUR FOOTPRINTS FROM THE GLEN ROSE FORMATION (PALUXY RIVER, DINOSAUR VALLEY STATE PARK, SOMERVELL COUNTY, TEXAS)

Dinosaur footprints are found in the Glen Rose Formation and other Lower Cretaceous stratigraphic units over much of central Texas (Pittman, 1989; Rogers, 2002; Farlow et al., 2006). Dinosaur tracks were discovered in the rocky bed of the Paluxy River, near the town of Glen Rose, Texas, early in the 20th Century (Jasinski, 2008; Farlow et al., 2012b). Ellis W. Shuler of Southern Methodist University did pioneering studies on the dinosaur tracks (Shuler 1917, 1935, 1937), and Langston (1974) summarized much of the early literature. What really put the dinosaur footprints of the Paluxy River on the map, though, were the herculean efforts that Roland T. Bird of the American Museum of Natural History made to secure trackway slabs for display at that institution and at the Texas Memorial Museum in Austin (Bird, 1985; Jasinski, 2008). In 1970 Dinosaur Valley State Park was created to protect the dinosaur footprints. This guidebook briefly summarizes earlier work, and also serves as an interim report of research of our group still in progress, concerned with identifying the makers of the Paluxy River footprints, and determining what those animals were up to as they made their tracks. We will offer some comparisons of the dinosaur tracks of the Glen Rose Formation with those from other ichnofaunas around the world. The last quarter-century has seen an explosive increase in the technical literature dealing with dinosaur footprints, and we cannot possibly cite all of the relevant studies. For the sake of brevity we will emphasize publications from the present century, and summary papers and books, as much as possible. Even with this restriction, however, the literature is so vast that the literature-cited “tail” of this report starts to wag the “dog” of the text

Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5α-dihydrotestosterone-PET: A Pilot Study

Most breast cancers express androgen receptors (AR). This prospective imaging sub-study explored imaging AR with (18)F-fluoro-5α-dihydrotestosterone (FDHT)-PET in patients with metastatic breast cancer (MBC) receiving selective AR modulation (SARM) therapy (GTx-024, GTx, Inc). Methods: 11 post-menopausal women with estrogen receptor positive MBC underwent FDHT-PET/CT at baseline, 6, and 12 weeks after starting SARM therapy. Abnormal tumor FDHT uptake was quantified using maximum SUV (SUVmax). AR status was determined from tumor biopsy specimens. FDHT-SUVmax percent change between scans was calculated. Best overall response was categorized as clinical benefit (CB: non-progressive disease [PD]), or PD using RECIST 1.1. Results: Median baseline FDHT-SUVmax was 4.1 (range 1.4-5.9) for AR+ tumors versus 2.3 (range 1.5-3.2) for AR- tumors (p=0.22). Quantitative AR expression and baseline FDHT uptake were weakly correlated (Pearson rho=0.39, p=0.30). Seven participants with CB at 12 weeks tended to have larger declines in FDHT uptake compared to those with PD at both 6 (median decline, range: -26.8%, -42.9 to -14.1% vs. -3.7%, -31% to +29%, respectively, p=0.11) and 12 weeks (median decline, range: -35.7%, -69.5 to -7.7% vs. -20.1%, -26.6% to +56.5%, respectively, p=0.17) after starting GTx-024. Conclusion: This hypothesis-generating data suggests that FDHT-PET/CT is worth further study as an imaging biomarker for evaluating response of MBC to SARM therapy and reiterates the feasibility of including molecular imaging in multidisciplinary therapeutic trials

Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the In-111 (111In)/yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin ®) theranostic pair in patients with lymphoma at myeloablative dose levels

PURPOSE: We prospectively evaluated the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin\u27s lymphoma using the theranostic pair of METHODS: 24 patients with CD20-positive relapsed or refractory rituximab-sensitive, low-grade, mantle cell, or diffuse large-cell NHL, with normal organ function, platelet counts \u3e 75,000/mm RESULTS: Patient-specific hybrid SPECT/CT + planar organ dosimetry was feasible in all 18 cases and used to determine the patient-specific therapeutic dose and guide dose escalation (26.8 ± 7.3 MBq/kg (mean), 26.3 MBq/kg (median) of CONCLUSIONS: Patient-specific outpatien

A Randomised Controlled Trial Assessing the Effect of Oral Diazepam on F-18-FDG Uptake in the Neck and Upper Chest Region

A distinctive pattern of physiological symmetrical uptake of F-18-fluorodeoxyglucose (F-18-FDG) in the neck and upper chest region is a phenomenon that is sometimes observed on positron emission tomography (PET) scans of some oncologic patients. Initially, it was assumed to be muscle uptake secondary to patient anxiety or tension, which could be prevented by diazepam treatment. However, PET-computed tomography data have shown that F-18-FDG uptake is not restricted to the musculature but is also localised within the non-muscular soft tissue, such as brown adipose tissue. The efficacy of benzodiazepine treatment to reduce this uptake has not been well established. Therefore, a randomised controlled trial was conducted to decide whether diazepam would decrease physiological F-18-FDG uptake in the neck and upper chest region (FDG-NUC). A randomised, double-blind, placebo-controlled trial was conducted to assess the effect on FDG-NUC of 5 mg diazepam, given orally 1 h before F-18-FDG injection. Patients younger than 40 years, having or suspected to have a malignancy, were eligible for inclusion. The primary endpoint was FDG-NUC, as assessed by visual analysis of whole-body PET scans by two independent observers. The secondary endpoint was clinical relevance of FDG-NUC. Fifty-two patients were included between September 2003 and January 2005. Twenty-eight patients (54%) received placebo; 24 (46%) received diazepam. FDG-NUC was seen in 25% of the patients in the diazepam group versus 29% in the placebo group. This difference was not statistically significant. No beneficial effect of administration of diazepam could be established. Pre-medication with benzodiazepines to diminish physiological uptake of F-18-FDG in the neck and upper chest region is not indicate

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Methods We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. Results At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the 177Lu-Dotatate group versus 3% in the control group (P<0.001). In the planned interim analysis of overall survival, 14 deaths occurred in the 177Lu-Dotatate group and 26 in the control group (P=0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the 177Lu-Dotatate group as compared with no patients in the control group, with no evidence of renal toxic effects during the observed time frame. Conclusions Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11

Design and Evaluation of a Propulsion Aid Device for Folding Wheelchairs

Upper-body injuries caused by overuse from manual wheelchair propulsion is a common challenge that many wheelchair users face. While there are propulsion aid devices on the market, these devices are often expensive, increase the footprint of the wheelchair, or do not provide the necessary requirements for physical movement and accessibility. Our team sought to create a propulsion aid that would address these issues by improving ease of use, enhancing maneuverability, and engaging in sustainable prototyping processes. After conducting research and interviews with wheelchair users, our team engaged in a year-long process entailing several design iterations, finite element analysis of components, and the fabrication of the device through CNC milling and adapting recycled materials. The final result is a functioning prototype of a tiller-controlled device and attachment system for folding wheelchairs that not only fulfills these requirements, but meets all necessary ADA and engineering standards for this category of medical device